Friedrich Alexander

Dec 3, 2024 | academic.oup.com | Francisco Martinez |Francisco Martínez |A Coruna |Bayer AG |Friedrich Alexander

Approximately 2.4% of worldwide mortality is related to chronic kidney disease (CKD) [1]. By 2040, CKD is expected to be the fifth leading cause of life-years lost worldwide [2]. Despite guideline-recommended interventions such as renin–angiotensin system (RAS) inhibition and sodium-glucose co-transporter-2 inhibitors (SGLT2is) [3, 4], patients with CKD remain at risk of disease progression, which may result in kidney replacement therapy [1, 5].

Jun 18, 2024 | academic.oup.com | Angel Y. S |Johannes F E |Friedrich Alexander

Cardiovascular disease is a leading cause of death globally, with older people and those with chronic kidney disease (CKD) at particularly high risk.1 Medications used to prevent cardiovascular events are prescribed based on evidence from randomized controlled trials.

Sep 15, 2023 | labmanager.com | Friedrich Alexander

Rock faces in Namibia are decorated with hundreds of stone-age images not only of animals and human footprints, but also of animal tracks. These have been largely neglected to date as researchers lacked the knowledge required to interpret them.

Mar 3, 2023 | labmanager.com | Friedrich Alexander

Today, the Academic Freedom Index (AFI) project presents its Update 2023, providing an overview of the state of academic freedom in 179 countries. The decline in academic freedom affects over 50 percent of the world's population, approximately 4 billion people. The Index identifies 22 countries where universities and scholars experience significantly less academic freedom today than they did 10 years ago. This includes democratic systems as well as autocratic countries.

Feb 28, 2023 | jamanetwork.com | Ajay Kirtane |Felix Mahfoud |Roland E. Schmieder |Friedrich Alexander

[Skip to Navigation] Figure 1.  Design of the 3 Studies Included in the Pooled AnalysisThe studies included in the pooled analysis are A Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN SOLO and TRIO) and A Study of the ReCor Medical Paradise System in Stage II Hypertension (RADIANCE II) trials.